Frataxin-deficient neurons and mice models of Friedreich ataxia are improved by TAT-MTScs-FXN treatment

View/ Open
Issue date
2018Author
Feldman, Anat
Osborne, Melissa
Greif, Hagar
Suggested citation
Britti, Elena;
Delaspre, Fabien;
Feldman, Anat;
Osborne, Melissa;
Greif, Hagar;
Tamarit Sumalla, Jordi;
Ros Salvador, Joaquim;
.
(2018)
.
Frataxin-deficient neurons and mice models of Friedreich ataxia are improved by TAT-MTScs-FXN treatment.
Journal of Cellular and Molecular Medicine, 2018, vol. 22, núm. 2, p. 834-848.
https://doi.org/10.1111/jcmm.13365.
Metadata
Show full item recordAbstract
Friedreich ataxia (FA) is a rare disease caused by deficiency of frataxin, a mitochondrial protein. As there is no cure available for this disease,
many strategies have been developed to reduce the deleterious effects of such deficiency. One of these approaches is based on delivering frataxin
to the tissues by coupling the protein to trans-activator of transcription (TAT) peptides, which enables cell membranes crossing. In this
study, we tested the efficiency of TAT-MTScs-FXN fusion protein to decrease neurodegeneration markers on frataxin-depleted neurons obtained
from dorsal root ganglia (DRG), one of the most affected tissues. In mice models of the disease, we tested the ability of TAT-MTScs-FXN to
penetrate the mitochondria and its effect on lifespan. In DRG neurons, treatment with TAT-MTScs-FXN increased cell survival, decreased neurite
degeneration and reduced apoptotic markers, such as a-fodrin cleavage and caspase 9 activation. Also, we show that heat-shock protein 60
(HSP60), a molecular chaperone targeted to mitochondria, suffered an impaired processing in frataxin-deficient neurons that was relieved by
TAT-MTScs-FXN addition. In mice models of the disease, administration of TAT-MTScs-FXN was able to reach muscle mitochondria, restore
the activity of the succinate dehydrogenase and produce a significant lifespan increase. These results support the use of TAT-MTScs-FXN as a
treatment for Friedreich ataxia.
Is part of
Journal of Cellular and Molecular Medicine, 2018, vol. 22, núm. 2, p. 834-848European research projects
Collections
The following license files are associated with this item:
Related items
Showing items related by title, author, creator and subject.
-
Metabolic remodeling in frataxin-deficient yeast is mediated by Cth2 and Adr1
Moreno Cermeño, Armando J.; Alsina Obiols, David; Cabiscol Català, Elisa; Tamarit Sumalla, Jordi; Ros Salvador, Joaquim (Elsevier, 2013)Frataxin is a mitochondrial protein involved in iron metabolism whose deficiency in humans causes Friedreich ataxia. We performed transcriptomic and proteomic analyses of conditional Yeast Frataxin Homologue (Yfh1) mutants ... -
Mitochondrial calcium signaling and neurodegenerative diseases
Britti, Elena; Delaspre, Fabien; Tamarit Sumalla, Jordi; Ros Salvador, Joaquim (Portland Press, 2018-11-16)Calcium is utilised by cells in signalling and in regulating ATP production; it also contributes to cell survival and, when concentrations are unbalanced, triggers pathways for cell death. Mitochondria contribute to calcium ... -
Major targets of iron-induced protein oxidative damage in frataxin-deficient yeasts are magnesium-binding proteins
Irazusta, Verónica Patricia; Moreno Cermeño, Armando J.; Cabiscol Català, Elisa; Ros Salvador, Joaquim; Tamarit Sumalla, Jordi (Elsevier, 2008)Iron accumulation has been associated with several pathological conditions such as Friedreich ataxia. This human disorder is caused by decreased expression of frataxin. Iron-overload triggers oxidative stress, but the ...